This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/resource/domain/vavai/subjekt/
n11http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
n9http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F13%3A10191993%21RIV14-MZ0-00064165/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F13%3A10191993%21RIV14-MZ0-00064165
rdf:type
n11:Vysledek skos:Concept
dcterms:description
Shortly after intermittent haemodialysis became established treatment of chronic renal failure, the first wearable artificial kidney (WAK) device projected or even constructed to solve the problem of intermittent treatment unphysiology. Successful development of hollow fibres enabled construction of a sufficiently small dialyzer to be worn and recirculation of dialysate through a sorbent cartridge lead to tremendous drop in dialysate volumes needed. Tested were WAK devices based both on haemodialysis (HD) or on haemofiltration (HF) (after highly permeable membranes became available) as well as on peritoneal dialysis (PD). Later, some other techniques and processes appeared in armamentarium of WAK designers, such as charged membranes, electrodialysis, nanotechnological processes enabling to create membranes with solute-specific pores. Also a few hybride constructions appeared during the last decade using membranes coated with tubular epithelial cells to mimic tubular resorption of biological kidney. With current trends towards more frequent HD with higher material costs, WAK effort got another impetus, this time purely economical. The first commercially available WAK (although still waiting for a CE mark in Europe and FDA clearing in USA) was developed by a Singaporean company AWAK Technologies in 2011. A European WAK is being developed as a joint project in frame of FP7 and is expected to be ready by 2014. However, acceptance of WAK instead of conventional intermittent therapy both by physicians and by the patients themselves still remains unresolved. Shortly after intermittent haemodialysis became established treatment of chronic renal failure, the first wearable artificial kidney (WAK) device projected or even constructed to solve the problem of intermittent treatment unphysiology. Successful development of hollow fibres enabled construction of a sufficiently small dialyzer to be worn and recirculation of dialysate through a sorbent cartridge lead to tremendous drop in dialysate volumes needed. Tested were WAK devices based both on haemodialysis (HD) or on haemofiltration (HF) (after highly permeable membranes became available) as well as on peritoneal dialysis (PD). Later, some other techniques and processes appeared in armamentarium of WAK designers, such as charged membranes, electrodialysis, nanotechnological processes enabling to create membranes with solute-specific pores. Also a few hybride constructions appeared during the last decade using membranes coated with tubular epithelial cells to mimic tubular resorption of biological kidney. With current trends towards more frequent HD with higher material costs, WAK effort got another impetus, this time purely economical. The first commercially available WAK (although still waiting for a CE mark in Europe and FDA clearing in USA) was developed by a Singaporean company AWAK Technologies in 2011. A European WAK is being developed as a joint project in frame of FP7 and is expected to be ready by 2014. However, acceptance of WAK instead of conventional intermittent therapy both by physicians and by the patients themselves still remains unresolved.
dcterms:title
Wearable artificial kidney - evolution of its concepts and current state-of-the-art Wearable artificial kidney - evolution of its concepts and current state-of-the-art
skos:prefLabel
Wearable artificial kidney - evolution of its concepts and current state-of-the-art Wearable artificial kidney - evolution of its concepts and current state-of-the-art
skos:notation
RIV/00064165:_____/13:10191993!RIV14-MZ0-00064165
n11:predkladatel
n17:ico%3A00064165
n4:aktivita
n16:I
n4:aktivity
I
n4:cisloPeriodika
2
n4:dodaniDat
n5:2014
n4:domaciTvurceVysledku
n7:1619004
n4:druhVysledku
n8:J
n4:duvernostUdaju
n14:S
n4:entitaPredkladatele
n9:predkladatel
n4:idSjednocenehoVysledku
117173
n4:idVysledku
RIV/00064165:_____/13:10191993
n4:jazykVysledku
n10:eng
n4:klicovaSlova
bioartificial device; sorption; peritoneal dialysis; haemodialysis; Wearable artificial kidney
n4:klicoveSlovo
n6:haemodialysis n6:Wearable%20artificial%20kidney n6:sorption n6:bioartificial%20device n6:peritoneal%20dialysis
n4:kodStatuVydavatele
CZ - Česká republika
n4:kontrolniKodProRIV
[DEBEBAD976F4]
n4:nazevZdroje
Lékař a technika
n4:obor
n12:FP
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
1
n4:rokUplatneniVysledku
n5:2013
n4:svazekPeriodika
43
n4:tvurceVysledku
Lopot, František
s:issn
0301-5491
s:numberOfPages
8